TSBX קפיטליזציה חשבונאית Turnstone Biologics Corp

Turnstone Biologics is developing a closed therapeutic cycle where cell selection patents make medical centers dependent on TSBX supplies. Serving as an assessment tool, this chart of value on GURU.Markets, where the indicator equals 0.01, complements data on patients retained in clinics for healing under FDA limits. The integration of viral code into lymphocytes creates a unique method for combating tumors, establishing it as a sole alternative solution.

This metric is calculated as the difference between total assets and liabilities, reflecting the actual value of equity and the issuer's financial autonomy. For Turnstone Biologics (TSBX), the trend in net assets demonstrates the company's ability to maintain costly alliances with oncology centers to create personalized immunotherapies, allowing investors to assess the resource base for implementing long-term research and development programs.